| Biomarker ID | 1571 |
| PMID | 31059955 |
| Year | 2019 |
| Biomarker | Osteopontin (OPN) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | increased with decreased BRFS |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.38 (95% CI: 1.06- 5.34) |
| Effect on Pathways | Pathway include: Integrin Pathway; ERK Signaling; Toll-like Receptor Signaling Pathway; ECM-receptor interaction; Focal Adhesion |
| Experiment | Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival |
| Type of Biomarker | Prognostic |
| Cohort | atients entered into a phase 3 randomised controlled trial of patients receiving EBRT (external beam radiotherapy) or EBRT (n=108) + HDR-BTb (n=110) (high-dose-rate brachytherapy boost). 204 samples were available after immunohistochemistry |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p < 0.036 |
| Method Used | Immunohistochemistry |
| Clinical | Yes |
| Remarks | NA |
| Clinical Trial Number | ISRCTN NO: ISRCTN98241100 |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |